Diabetic Retinopathy/Diabetic Macular Edema | TreatmentTrends | US | 2014
This report provides detailed analysis of the current and projected mar-kets for diabetic retinopathy (DR) and diabetic macular edema (DME). The DR population represents more than 5.8 million diagnosed patients in the U.S. with 2.3 million DR patients also suffering from DME.
TreatmentTrends: Diabetic Retinopathy/Diabetic Macular Edema (U.S.) is an annual syndicated report series that offers a snapshot of DR and DME market dynamics and competitive landscape through comprehensive primary research with retinal specialists and general ophthalmologists. The report covers the current use of intravitreal injec-tions, in particular anti-VEGF agents, for the treatment of DME, as well as attitudes and perceptions toward these products, advantages and disadvantages, ideal patient types, barriers to growth, promotional activ-ity, and anticipated use. In addition, respondents are queried about their awareness of and interest in products in development.
